Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo

Trends in Neurosciences

Volumn 27, Issue 2, 2004, Pages 66-69

  Hernández, Félix ^a   Díaz Hernández, Miguel ^a   Avila, Jesús ^a   Lucas, José J ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; PROTEASOME; UBIQUITIN;

ANALYTIC METHOD; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

EID: 0347449543     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2003.12.002     Document Type: Short Survey

References (33)

1. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82:2002;373-428.
2. Lindsten K., et al. A transgenic mouse model of the ubiquitin/proteasome system. Nat. Biotechnol. 21:2003;897-902.
3. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.
4. Schwartz A.L., Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 50:1999;57-74.
5. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.
6. Goedert M., et al. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr. Opin. Neurobiol. 8:1998;619-632.
7. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:1998;605-608.
8. Leroy E., et al. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
9. Liu Y., et al. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell. 111:2002;209-218.
10. Keller J.N., et al. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75:2000;436-439.
11. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297:2001;191-194.
12. Díaz-Hernández, M. et al. Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci. (in press).
13. Bence N.F., et al. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
14. Ding Q., et al. Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. J. Biol. Chem. 277:2002;13935-13942.
15. Jana N.R., et al. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10:2001;1049-1059.
16. Nishitoh H., et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 16:2002;1345-1355.
17. McGuire M.J., et al. The high molecular weight multicatalytic proteinase, macropain, exists in a latent form in human erythrocytes. Biochim. Biophys. Acta. 995:1989;181-186.
18. Kisselev A.F., et al. Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings. J. Biol. Chem. 277:2002;22260-22270.
19. Voges D., et al. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68:1999;1015-1068.
20. Dantuma N.P., et al. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat. Biotechnol. 18:2000;538-543.
21. Stack J.H., et al. A ubiquitin-based tagging system for controlled modulation of protein stability. Nat. Biotechnol. 18:2000;1298-1302.
22. Illing M.E., et al. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem. 277:2002;34150-34160.
23. Petrucelli L., et al. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 36:2002;1007-1019.
24. Verhoef L.G., et al. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum. Mol. Genet. 11:2002;2689-2700.
25. Saudou F., et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 95:1998;55-66.
26. Martin-Aparicio E., et al. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J. Neurosci. 21:2001;8772-8781.
27. Guidetti P., et al. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp. Neurol. 169:2001;340-350.
28. Hansson O., et al. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. U. S. A. 96:1999;8727-8732.
29. Wong P.C., et al. Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci. 5:2002;633-639.
30. Rubinsztein D.C. Lessons from animal models of Huntington's disease. Trends Genet. 18:2002;202-209.
31. Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8:2001;739-758.
32. Lindsten K., et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J. Cell Biol. 157:2002;417-427.
33. Johnson E.S., et al. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J. Biol. Chem. 270:1995;17442-17456.